“…Thrombopoietin peptide mimetic, romiplostim (Nplate ™ , formerly, AMG 531), and TPO non‐peptide mimetic, eltrombopag (Promacta ™ , formerly, SB 497115‐GR) were approved by FDA for the treatment of chronic ITP patients who were refractory to the prior therapy in 2008. Currently, at least two TPO peptide mimetics (romiplostim, RWJ‐800088) and four TPO non‐peptide mimetics (eltrombopag, AKR‐501, LGD‐4665, S‐888711) are in clinical trials (Table 1) [11–17]. There are several other thrombopoietic compounds, such as NIP‐004, butyzamide, Fab59, VB22B sc(Fv) 2 , MA01G4344U, in preclinical trials [18–22].…”